Why the UK medicine supply chain is dangerously exposed to global shocks

**Lead**

The United Kingdom’s medicine supply chain is dangerously exposed to global shocks, with a growing consensus among health experts and industry bodies that the nation’s dependence on a narrow set of overseas suppliers for active pharmaceutical ingredients (APIs) and finished medicines poses a systemic risk to patient care. Disruptions ranging from the COVID-19 pandemic to the blockage of the Suez Canal and the war in Ukraine have repeatedly exposed the fragility of a system built on cost efficiency rather than resilience, prompting calls for urgent reform.

**Context**

The UK imports the vast majority of its medicines. According to data from the Department of Health and Social Care, roughly three-quarters of all medicines used in the NHS are either wholly manufactured abroad or contain APIs sourced from overseas. China and India dominate the global production of APIs, accounting for an estimated 60 per cent and 20 per cent respectively of the world’s supply. Finished medicinal products, including many generic drugs, are largely sourced from European Union countries, with Germany, France and Italy among the top suppliers.

Brexit has added friction to this already fragile system. The end of the transition period in 2021 introduced customs checks, additional paperwork and delays at ports, particularly for medicines that rely on rapid, just-in-time delivery. The British Generic Manufacturers Association has repeatedly warned that stockpiles of certain essential drugs, including antibiotics, statins and antidepressants, have fallen to dangerously low levels because of border friction and global supply chain pressures.

During the COVID-19 pandemic, the UK experienced acute shortages of paracetamol, ibuprofen and some anaesthetics. More recently, the war in Ukraine disrupted supplies of helium, a critical gas used in MRI scanners, and of certain raw materials for pharmaceuticals. The 2021 blockage of the Suez Canal by the Ever Given container ship delayed shipments of APIs and finished products for weeks, highlighting how a single incident can ripple through the entire supply chain.

A 2023 report by the House of Commons Health and Social Care Committee concluded that the UK’s medicine supply chain is “not fit for purpose” and that the Government’s reliance on voluntary arrangements with industry is insufficient to guarantee continuity of supply. The committee noted that the Department of Health and Social Care does not have full visibility of the end-to-end supply chain, making it difficult to anticipate and mitigate risks.

**Analysis**

The vulnerability of the UK’s medicine supply chain is not merely an operational inconvenience; it is a matter of patient safety and national security. When a critical medicine runs short, clinicians are forced to substitute alternatives, which may be less effective, cause side effects or require different dosing regimens. In extreme cases, patients may face delayed treatment or rationing. The NHS has a statutory duty to ensure continuity of supply, but the current system relies heavily on the goodwill of manufacturers and wholesalers to maintain buffer stocks.

Geopolitical tensions are compounding the risk. The US-China trade war, the ongoing conflict in Ukraine and instability in the Middle East all threaten the flow of raw materials and finished products. Climate change is also emerging as a factor: extreme weather events, such as floods in China’s pharmaceutical manufacturing hubs or droughts affecting water-intensive production, could cause sudden shortages. The COVID-19 pandemic demonstrated that when global demand surges simultaneously, countries prioritise their own populations, leaving import-dependent nations like the UK at the back of the queue.

Efforts to reshore pharmaceutical manufacturing have been announced, including a £20 million government fund for small-scale production of critical medicines and a strategy to boost domestic API capacity. However, industry experts caution that rebuilding a domestic supply chain will take years and require significant investment. The cost of building a single API plant can run into hundreds of millions of pounds, and regulatory approval for new manufacturing sites is a lengthy process. Moreover, the UK lacks the skilled workforce and raw material base that countries like India and China have built over decades.

Diversification of supply sources is another proposed solution. The Government has encouraged the Medicines and Healthcare products Regulatory Agency (MHRA) to approve more overseas suppliers, particularly from countries such as Canada, Australia and Japan. Yet this approach also has limits: many of these nations face similar challenges of their own, and global competition for limited production capacity is intensifying.

**Fontes**

- House of Commons Health and Social Care Committee, “Medicine Shortages: Report of Session 2022–23” (2023). - British Generic Manufacturers Association, “Supply Chain Resilience: The Case for UK Medicines Manufacturing” (2024). - Department of Health and Social Care, “Medicines Supply Strategy: Securing the Future” (2023). - NHS England, “Supply Chain Vulnerability Assessment for Essential Medicines” (internal briefing, 2022). - The King’s Fund, “The UK’s Medicines Supply Chain: Risks and Remedies” (2024).